1-12 of 309 Products & Services
This spray chamber Helix™ locking screw is used with ELAN® 6000, 9000, DRC II, and DRC-e ICP-MS series instruments.
This SeaSpray™ nebulizer is used with NexION® 1000 and 2000 ICP-MS series instruments. The SeaSpray™ Concentric Nebulizer is ideal for samples with high dissolved solids and offers outstanding nebulization efficiency for trace level analysis. It offers freedom from clogging while nebulizing solutions near the limit of solubility of most mineral salts and conferring significant sensitivity gains. All SeaSpray™ Nebulizers are supplied with the EzyLok Argon connector.
This PFA MicroFlow™ Nebulizer with Integrated Autosampler Probe is for Avio® and Optima® ICP-OES series instruments, as well as NexION® 300/350 ICP-MS series instruments. These nebulizers self-aspirate at low flow rates with any autosampler and provide the same benefits of the PFA MicroFlow nebulizer. MicroFlow™ nebulizers are resistant to clogging, reliably self-aspirated or pumped to produce a fine aerosol for high transport efficiency and high sensitivity. The integrated sampling probe is constructed by encapsulating a rigid support material between layers of PFA to provide a chemically-resistant probe that is mechanically stable and resilient.
This MicroMist™ Nebulizer is used with NexION® 1000 and 2000 ICP-MS series instruments. The MicroMist™ micro-uptake glass concentric nebulizer offers high performance for limited sample volumes.
This o-ring-free demountable quartz torch is used with all ELAN® 5000, 6x00, 9000, DRC II, and DRC-e, and all NexION® 300 and 350 ICP-MS series instruments.
1-1 of 1 Business Insights
Nanoparticles (NPs) have been of significant interest over the last two decades as they offer attractive benefits for drug delivery to overcome limitations in conventional chemotherapy. Nanoparticles can be engineered to carry both drugs and imaging probes to simultaneously detect and treat cancer. They may also be designed to specifically target diseased tissues and cells in the body. A number of nanoparticlebased cancer therapeutics have been approved for clinical use and/or are currently under development.